• JW Life Science’s third-quarter 2026 operating profit rose 22.07% year over year to KRW 8.02 billion.
• Net income increased 31.85% from a year earlier to KRW 6.09 billion.
• Revenue slipped 0.14% year over year to KRW 56.66 billion.
• For the first nine months of 2026, net income fell 10.73% to KRW 18.94 billion.
• Cumulative operating profit edged up 1.14% to KRW 24.78 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Life Science Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105800786), on November 05, 2026, and is solely responsible for the information contained therein.